New Applications of Heparin and Other Glycosaminoglycans

Detalhes bibliográficos
Autor(a) principal: Lima, Marcelo [UNIFESP]
Data de Publicação: 2017
Outros Autores: Rudd, Timothy, Yates, Edwin [UNIFESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
dARK ID: ark:/48912/001300000vfm1
DOI: 10.3390/molecules22050749
Texto Completo: http://dx.doi.org/10.3390/molecules22050749
https://repositorio.unifesp.br/handle/11600/54540
Resumo: Heparin, the widely used pharmaceutical anticoagulant, has been in clinical use for well over half a century. Its introduction reduced clotting risks substantially and subsequent developments, including the introduction of low-molecular-weight heparin, made possible many major surgical interventions that today make heparin an indispensable drug. There has been a recent burgeoning of interest in heparin and related glycosaminoglycan (GAG) polysaccharides, such as chondroitin sulfates, heparan sulfate, and hyaluronate, as potential agents in various applications. This ability arises mainly from the ability of GAGs to interact with, and alter the activity of, a wide range of proteins. Here, we review new developments (since 2010) in the application of heparin and related GAGs across diverse fields ranging from thrombosis and neurodegenerative disorders to microbiology and biotechnology.
id UFSP_d4f1827169c5f76e8f13d774d9380d2c
oai_identifier_str oai:repositorio.unifesp.br/:11600/54540
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling New Applications of Heparin and Other Glycosaminoglycansheparinglycosaminoglycanschondroitin sulfateHeparin, the widely used pharmaceutical anticoagulant, has been in clinical use for well over half a century. Its introduction reduced clotting risks substantially and subsequent developments, including the introduction of low-molecular-weight heparin, made possible many major surgical interventions that today make heparin an indispensable drug. There has been a recent burgeoning of interest in heparin and related glycosaminoglycan (GAG) polysaccharides, such as chondroitin sulfates, heparan sulfate, and hyaluronate, as potential agents in various applications. This ability arises mainly from the ability of GAGs to interact with, and alter the activity of, a wide range of proteins. Here, we review new developments (since 2010) in the application of heparin and related GAGs across diverse fields ranging from thrombosis and neurodegenerative disorders to microbiology and biotechnology.Fed Univ Sao Paulo UNIFESP, Dept Biochem, BR-04044020 Sao Paulo, SP, BrazilUniv Liverpool, Inst Integrat Biol, Dept Biochem, Crown St, Liverpool L69 7ZB, Merseyside, EnglandNatl Inst Biol Stand & Controls, Blanche Lane, Potters Bar EN6 3QG, Herts, EnglandFed Univ Sao Paulo UNIFESP, Dept Biochem, BR-04044020 Sao Paulo, SP, BrazilWeb of ScienceMdpi Ag2020-07-13T11:53:19Z2020-07-13T11:53:19Z2017info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion-http://dx.doi.org/10.3390/molecules22050749Molecules. Basel, v. 22, n. 5, p. -, 2017.10.3390/molecules22050749WOS000404522900072.pdf1420-3049https://repositorio.unifesp.br/handle/11600/54540WOS:000404522900072ark:/48912/001300000vfm1engMoleculesBaselinfo:eu-repo/semantics/openAccessLima, Marcelo [UNIFESP]Rudd, TimothyYates, Edwin [UNIFESP]reponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2021-09-29T14:54:12Zoai:repositorio.unifesp.br/:11600/54540Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-12-11T20:39:25.132067Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv New Applications of Heparin and Other Glycosaminoglycans
title New Applications of Heparin and Other Glycosaminoglycans
spellingShingle New Applications of Heparin and Other Glycosaminoglycans
New Applications of Heparin and Other Glycosaminoglycans
Lima, Marcelo [UNIFESP]
heparin
glycosaminoglycans
chondroitin sulfate
Lima, Marcelo [UNIFESP]
heparin
glycosaminoglycans
chondroitin sulfate
title_short New Applications of Heparin and Other Glycosaminoglycans
title_full New Applications of Heparin and Other Glycosaminoglycans
title_fullStr New Applications of Heparin and Other Glycosaminoglycans
New Applications of Heparin and Other Glycosaminoglycans
title_full_unstemmed New Applications of Heparin and Other Glycosaminoglycans
New Applications of Heparin and Other Glycosaminoglycans
title_sort New Applications of Heparin and Other Glycosaminoglycans
author Lima, Marcelo [UNIFESP]
author_facet Lima, Marcelo [UNIFESP]
Lima, Marcelo [UNIFESP]
Rudd, Timothy
Yates, Edwin [UNIFESP]
Rudd, Timothy
Yates, Edwin [UNIFESP]
author_role author
author2 Rudd, Timothy
Yates, Edwin [UNIFESP]
author2_role author
author
dc.contributor.author.fl_str_mv Lima, Marcelo [UNIFESP]
Rudd, Timothy
Yates, Edwin [UNIFESP]
dc.subject.por.fl_str_mv heparin
glycosaminoglycans
chondroitin sulfate
topic heparin
glycosaminoglycans
chondroitin sulfate
description Heparin, the widely used pharmaceutical anticoagulant, has been in clinical use for well over half a century. Its introduction reduced clotting risks substantially and subsequent developments, including the introduction of low-molecular-weight heparin, made possible many major surgical interventions that today make heparin an indispensable drug. There has been a recent burgeoning of interest in heparin and related glycosaminoglycan (GAG) polysaccharides, such as chondroitin sulfates, heparan sulfate, and hyaluronate, as potential agents in various applications. This ability arises mainly from the ability of GAGs to interact with, and alter the activity of, a wide range of proteins. Here, we review new developments (since 2010) in the application of heparin and related GAGs across diverse fields ranging from thrombosis and neurodegenerative disorders to microbiology and biotechnology.
publishDate 2017
dc.date.none.fl_str_mv 2017
2020-07-13T11:53:19Z
2020-07-13T11:53:19Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.3390/molecules22050749
Molecules. Basel, v. 22, n. 5, p. -, 2017.
10.3390/molecules22050749
WOS000404522900072.pdf
1420-3049
https://repositorio.unifesp.br/handle/11600/54540
WOS:000404522900072
dc.identifier.dark.fl_str_mv ark:/48912/001300000vfm1
url http://dx.doi.org/10.3390/molecules22050749
https://repositorio.unifesp.br/handle/11600/54540
identifier_str_mv Molecules. Basel, v. 22, n. 5, p. -, 2017.
10.3390/molecules22050749
WOS000404522900072.pdf
1420-3049
WOS:000404522900072
ark:/48912/001300000vfm1
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Molecules
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv -
dc.coverage.none.fl_str_mv Basel
dc.publisher.none.fl_str_mv Mdpi Ag
publisher.none.fl_str_mv Mdpi Ag
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1822251013463080960
dc.identifier.doi.none.fl_str_mv 10.3390/molecules22050749